摘要
目的观察重组人血管内皮抑制素(恩度)联合IFL方案(CPT-11+5-Fu/LV)治疗晚期结肠癌的近期疗效和毒副反应。方法试验组:恩度联合CPT-11+5-Fu/LV方案和对照组CPT-11+5-Fu/LV方案治疗晚期结肠癌共60例,共2～4周期,按照ERCIST标准和NCI-CTC标准分别评价二组的近期疗效和毒副反应。结果试验组有效率(RR)76.7%,疾病控制率(DCR)93.3%;对照组有效率(RR)46.6%,疾病控制率59.9%。二组对比差异有统计学意义(P<0.05)。近期毒副反应主要有胆碱能综合征,腹泻,骨髓抑制,胃肠道反应,口腔黏膜炎等,二组对比差异无统计学意义(P>0.05)。结论恩度联合IFL方案治疗晚期结肠癌,近期疗效提高,毒副反应不增加,安全性较好。
Objective To observe the curative effect and the side effects of endostar（recombinant human endostatin,rh-endostain）combined IFL regimen [leucovorin（LV）,5-fluorouracil（5-Fu）and Irinotecan（CPT-11）CPT-11＋5-Fu/LV] in patients with advanced colorectal cancer.Methods A total of 60 patients with advanced colorectal cancer entered this trial.They were randomly and equally divided into endostar combined CPT-11＋5-Fu/LV group and CPT-11＋5-Fu/LV group.The cases were evaluated after at least 2-4 courses.The curative effect and the side effects were evaluated according to RECIST and NCI - CTC criteria. Results The response rate was 76.7 0% and the disease control rate was 93.3 % in trial group. The response rate was 46.6 % and the disease control rate was 59.9 % in contral group. There were significantly difference between two groups （P〈0. 05）. The main short-term toxicity effects were cholinergic syndrome, diarrhea, neutropenia, nausea, vomiting and mucositis, et al. There were.no difference between the two groups （P〉0.05）. Concision Endostar combined CPT - 11 ＋ 5 - Fu/LV in the treatment of advanced colorectal cancer patients were safe, effective and the toxicity is tolerable.
出处
《中国煤炭工业医学杂志》
2009年第8期1179-1180,共2页
Chinese Journal of Coal Industry Medicine
关键词
重组人血管内皮抑制素
化学治疗
伊立替康
氟尿嘧啶
亚叶酸钙
结肠癌
晚期
recombinant human endostatin
chemotherapeutics
irinotecan
fluorouracil
calcium folinate
colon carcinoma
advanced stage
